You are here: Industry Insights > Immuno-Oncology

News List

Oncolytics Biotech Announces FDA Fast Track for Reolysin americanpharmaceuticalreview
May 09, 2017
Oncolytics Biotech announced the United States Food and Drug Administration (FDA) granted Fast Track designation for Reolysin, the company's proprietary immuno-oncology viral agent, for the treatment of metastatic breast cancer.
AstraZeneca, Heptares in Immuno-oncology Pact contractpharma
April 11, 2017
AstraZeneca and Heptares Therapeutics have entered into a licensing agreement under which AstraZeneca will acquire exclusive global rights to develop.
Indian FDA Approves the First Autologous Dendritic Cell-Based Immuno-Oncology Product americanpharmaceuticalreview
April 07, 2017
A first-of-its-kind Indian biotechnology company, APAC Biotech, was granted with a commercial license by Indian FDA...
Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb and the Cancer Research Institute an worldpharmanews
March 29, 2017
The Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb Company (NYSE: BMY) and the Cancer Research Institute (CRI) today announced a multi-year clinical research collaboration.
Roche lines up Bavarian Nordic vaccine for Tecentriq combo test in bladder cancer fiercepharma
March 16, 2017
Combinations are where it's at in immuno-oncology these days, and Merck & Co. and Bristol-Myers Squibb have each paired their PD-1 meds with cancer vaccines from smaller players. Now, third-to-the-field Roche is following that strategy with its own offeri
Synthon and Sanquin to Develop Immuno-Oncology Therapeutic Leads Modulating the CD47-SIRPa Pathway americanpharmaceuticalreview
March 06, 2017
Synthon Biopharmaceuticals BV, an international biopharmaceutical company that is focused on developing new...
Bristol-Myers Squibb expands International Immuno-Oncology Network (II-ON) worldpharmanews
February 28, 2017
Bristol-Myers Squibb Company (NYSE:BMY) today announced that Columbia University Medical Center and Peter MacCallum Cancer Centre (Peter Mac) have joined the International Immuno-Oncology Network (II-ON).
Merus closes global strategic research collaboration with Incyte pharmaceutical-technology
January 26, 2017
Netherlands-based Immuno-oncology company Merus has closed its previously announced global strategic research collaboration with Incyte.
Merck announces research collaboration with Domain Therapeutics in immuno-oncology worldpharmanews
January 24, 2017
Merck announced it has entered into a collaboration and licensing agreement with Domain Therapeutics, Strasbourg, France, to explore the potential of adenosine inhibition in the development of novel immuno-oncology agents.
Merck KGaA, Domain Explore New Immuno-oncology Agents contractpharma
January 24, 2017
Will work to develop and test new agents targeting key adenosine receptors

Previous page 1 2 3 4 5 6 7 8 9 10 Next page